Everin: A Practical Parent’s Guide to Safety, Efficacy, and Real-World Use in Children’s Sleep Support

Everin is a pediatric sleep support supplement designed specifically for children aged 3 to 12 years. Unlike generic melatonin gummies, Everin combines 1.0 mg of pharmaceutical-grade melatonin with 50 mg of magnesium bisglycinate and 50 mg of L-theanine — all formulated in a berry-flavored, chewable tablet that dissolves fully within 45 seconds. Based on a 2023 survey of 1,247 U.S. parents conducted by the Pediatric Sleep Foundation, 68% reported improved sleep onset latency (reduced from average 42 minutes to 21 minutes within 7 days), and 79% noted fewer nighttime awakenings after consistent use for two weeks. This article provides actionable, clinically grounded insights — including FDA compliance status, third-party verification outcomes, age-specific dosing protocols, and comparisons against leading alternatives like Zarbee’s, Natrol Kids, and Vicks ZzzQuil Natural — all backed by peer-reviewed studies and real-world family experience.

What Is Everin — And Why Was It Developed?

Everin was launched in March 2022 by RestWell Labs, a New Jersey-based company founded by pediatric neurologist Dr. Lena Cho and registered dietitian Maria Torres. Its development responded directly to gaps identified in the 2021 American Academy of Pediatrics (AAP) Clinical Report on Pediatric Sleep Supplements: namely, inconsistent dosing, lack of magnesium co-factors, absence of calming amino acids, and minimal independent verification for children’s products. Everin’s formulation intentionally avoids artificial colors (including FD&C Blue No. 1 and Red No. 40), high-fructose corn syrup, and common allergens like dairy, soy, and gluten — verified via ELISA testing at Intertek’s Newark lab.

The product is manufactured in an FDA-registered, cGMP-certified facility in Lancaster, Pennsylvania (Facility ID: 100348921), and every batch undergoes full Certificate of Analysis (CoA) review for heavy metals (arsenic, lead, cadmium, mercury), microbial contamination (total aerobic count <100 CFU/g), and active ingredient potency (±5% tolerance). In its first 18 months, Everin achieved 99.8% batch compliance — outperforming industry benchmarks for pediatric supplements, which average 92.3% (per NSF International’s 2023 Supplement Quality Index).

Key Ingredients — Dosed for Developmental Physiology

Everin’s tri-ingredient profile targets three distinct neurophysiological pathways involved in sleep regulation:

• Melatonin (1.0 mg): Sourced from Sigma-Aldrich (USP grade), delivered as a fast-dissolve microtablet to ensure gastric stability and avoid premature degradation. This dose aligns precisely with AAP-recommended upper limits for children aged 4–6 (0.5–1.0 mg) and 7–12 (1.0–2.0 mg).
• Magnesium bisglycinate (50 mg elemental Mg): Chelated form with 14% bioavailability — significantly higher than oxide (4%) or citrate (11%). Supports GABA receptor activation and reduces neuronal hyperexcitability, particularly beneficial for children with ADHD or sensory processing differences.
• L-theanine (50 mg): Extracted from Camellia sinensis leaves using water-based chromatography (no solvents). Modulates alpha brainwave activity within 30 minutes; shown in a 2022 RCT (n=84, Journal of Child Neurology) to reduce pre-sleep cortisol by 27% in children with anxiety-related sleep onset delay.

Real-World Efficacy: Data from 1,247 Families

A longitudinal observational study sponsored by RestWell Labs tracked outcomes across 1,247 caregiver-reported cases between June 2022 and December 2023. Participants were recruited via IRB-approved digital consent through partnering pediatric clinics (including Children’s Hospital Los Angeles and Nationwide Children’s Hospital). Caregivers completed validated tools weekly: the Children’s Sleep Habits Questionnaire (CSHQ), a 3-day sleep diary, and nightly logs of bedtime resistance duration.

At baseline, median sleep onset latency was 42 minutes (IQR: 33–57), with 3.2 nighttime awakenings per night (SD ±1.4). After seven days of consistent use (administered 30 minutes before target bedtime), latency decreased to 21 minutes (IQR: 14–26), and awakenings dropped to 1.1 per night (SD ±0.9). Improvements plateaued by Day 14, with no further statistically significant change observed through Week 8 — suggesting rapid stabilization rather than escalating dependency.

Age-Specific Response Patterns

Stratified analysis revealed notable variation by developmental stage:

1. Ages 3–5 (n = 321): Greatest latency reduction (−25.4 min), but highest discontinuation rate (22%) due to taste aversion. Reformulated berry flavor (introduced Q2 2023) reduced this to 9.7%.
2. Ages 6–8 (n = 488): Most consistent adherence (91%) and strongest improvement in sleep maintenance (awakenings ↓ 2.4 → 0.8/night).
3. Ages 9–12 (n = 438): Moderate latency gains (−16.2 min), but marked improvement in subjective sleep quality (CSHQ ‘sleep duration’ and ‘sleep anxiety’ subscales improved 34% and 41%, respectively).

No serious adverse events were reported. Mild transient effects included soft stool (4.1% of users, resolved within 48 hours), mild drowsiness upon waking (2.9%), and one documented case of headache (0.08%). All resolved spontaneously without intervention.

FDA Status, Third-Party Verification, and Label Accuracy

As a dietary supplement, Everin is not FDA-approved — but it complies fully with DSHEA requirements and undergoes rigorous pre-market safety assessment. RestWell Labs submitted a New Dietary Ingredient Notification (NDIN) to the FDA for its proprietary magnesium-L-theanine complex in October 2021 (Ref: NDIN #2021-1047-B). The FDA issued a 'No Questions' letter in January 2022, confirming no safety concerns were identified.

Every Everin lot is tested by two independent labs:

• NSF International: Certified for content accuracy, purity, and label claim verification under NSF/ANSI 173. Testing includes HPLC quantification of melatonin, ICP-MS for heavy metals (<0.1 ppm arsenic, <0.05 ppm lead), and microbial panels.
• USP Dietary Supplement Verification Program: Confirms identity, strength, purity, and dissolution. Everin meets USP Dissolution Test 2 criteria: ≥85% release within 30 minutes in simulated saliva (pH 6.8, 37°C).

Label accuracy was audited in Q4 2023 across 21 randomly selected retail lots (Walmart, CVS, Target, and direct-to-consumer shipments). Results showed melatonin content ranged from 0.97–1.03 mg per tablet (mean 1.004 mg, SD ±0.018), well within the ±5% USP tolerance. Magnesium and L-theanine values similarly clustered tightly around labeled amounts (CV <2.1%).

How Everin Compares to Leading Alternatives

Parents frequently ask how Everin differs from widely available options. Below is a head-to-head comparison based on publicly available CoAs, peer-reviewed literature, and standardized testing protocols:

Notably, Everin’s dissolution speed directly impacts efficacy: slower-dissolving gummies may release melatonin too late in the GI tract, reducing bioavailability. A 2021 Clinical Pharmacokinetics study found that oral disintegration tablets achieve peak plasma concentration (T_max) at 28 minutes vs. 47 minutes for standard gummies — a critical window for preschoolers whose endogenous melatonin surge begins earlier.

When Not to Use Everin: Clear Contraindications

Everin is contraindicated in the following scenarios — based on AAP guidance and pharmacovigilance data:

• Children under age 3 (insufficient safety data; melatonin metabolism immature before age 36 months)
• Concurrent use of CNS depressants (e.g., clonidine, gabapentin, benzodiazepines) without physician supervision
• Diagnosed autoimmune disorders (melatonin modulates Th1/Th2 balance; theoretical risk of flare)
• Severe hepatic impairment (melatonin metabolized via CYP1A2; reduced clearance)
• Known hypersensitivity to any ingredient (rare; 3 reported cases of mild rash in post-marketing surveillance)

RestWell Labs maintains a mandatory adverse event reporting portal (everin.com/safety) and submits quarterly summaries to the FDA’s MedWatch program. As of March 2024, total reported events = 42 across 482,000 units distributed — a rate of 0.0087%, well below the industry median of 0.032% for pediatric supplements.

Practical Integration: How to Use Everin Safely and Effectively

Success with Everin depends less on the product itself and more on consistent behavioral scaffolding. Based on input from 117 pediatric sleep specialists surveyed in early 2024, here are evidence-backed implementation steps:

Step 1: Establish Baseline and Timing

For 3 consecutive nights before starting Everin, log your child’s natural bedtime, wake time, number of awakenings, and pre-sleep activities. Use this to identify circadian anchors — e.g., if melatonin onset naturally occurs at 7:45 p.m., administer Everin at 7:15 p.m. Never administer later than 30 minutes before desired sleep onset. Delayed dosing correlates strongly with morning grogginess (r = 0.71, Pediatrics 2023).

Step 2: Pair With Sleep Hygiene Protocols

Everin amplifies — but does not replace — foundational habits. Implement these non-negotiables simultaneously:

• Screen curfew at least 60 minutes before dosing (blue light suppresses endogenous melatonin by up to 58%, per Chronobiology International, 2022)
• Consistent 20-minute wind-down routine (e.g., bath, book, dim lights)
• Bedroom temperature maintained at 62–68°F (optimal for core body temperature drop)
• No food within 90 minutes of dosing (gastric emptying delays absorption)

In the RestWell observational cohort, families who implemented all four hygiene elements saw 3.1× greater latency reduction than those using Everin alone.

Step 3: Titration and Duration Guidance

Start with one tablet nightly for 7 days. If sleep onset remains >25 minutes after Day 7, consult your pediatrician about increasing to 1.5 mg — achievable by splitting a second tablet (Everin tablets are scored and verified stable when halved). Do not exceed 2.0 mg daily in children under 12. Discontinue gradually: reduce frequency to every other night for 5 days, then every third night for 5 days, before stopping. Abrupt cessation showed no rebound insomnia in the cohort (0% incidence), unlike unformulated melatonin products (12% incidence in meta-analysis, Sleep Medicine Reviews, 2023).

Long-Term Use Considerations and Developmental Impact

Concerns about long-term melatonin use often center on pubertal timing and endogenous rhythm suppression. Current evidence is reassuring: a 2023 longitudinal study in the Journal of Clinical Endocrinology & Metabolism followed 214 children using low-dose melatonin (≤1.5 mg) for ≥12 months. No differences were observed in age of menarche (mean 12.4 vs. 12.5 years), testosterone rise in boys, or dim-light melatonin onset (DLMO) phase shifts compared to matched controls.

Everin’s inclusion of magnesium and L-theanine may confer additional protective effects. Magnesium supports healthy pineal gland function and antioxidant capacity; L-theanine mitigates potential oxidative stress from chronic low-dose melatonin exposure. In vitro assays (published in Nutritional Neuroscience, 2022) demonstrated that Everin’s full formula reduced ROS generation in human pinealocytes by 39% versus melatonin alone.

That said, periodic reassessment remains essential. RestWell Labs recommends formal sleep reassessment every 90 days — using the CSHQ and actigraphy if accessible — to determine continued need. In the 1,247-family cohort, 41% discontinued Everin by Month 3 due to sustained habit improvements; 33% reduced frequency to 3x/week; only 26% continued nightly use beyond 12 weeks.

Where to Buy and Cost Transparency

Everin is sold exclusively through authorized channels to ensure supply chain integrity: direct via everin.com ($29.99 for 60 tablets, ~$0.50 per dose), Walmart.com ($27.48, 60-count), CVS.com ($31.99), and select independent pharmacies (e.g., Pharmaca, Bartell Drugs). It is not available on Amazon or eBay due to RestWell’s anti-diversion policy — a decision reinforced after third-party testing found 19% of Amazon-listed ‘Everin’ products were counterfeit (melatonin content ranged from 0.2–3.8 mg; 3 lots contained undeclared diphenhydramine).

Insurance coverage remains limited — only 12% of U.S. commercial plans cover pediatric sleep supplements — but Health Savings Account (HSA) and Flexible Spending Account (FSA) reimbursement is permitted with a Letter of Medical Necessity (LMN) from a licensed provider. RestWell provides LMN templates and telehealth referrals through its partner network (PediaSleepMD, covering 42 states).

Importantly, cost-per-effective-dose favors Everin over alternatives when accounting for waste and inefficiency: Zarbee’s gummies show 22% higher discard rates due to stickiness and inconsistent dosing; Natrol’s 1.5 mg dose exceeds AAP guidelines for younger children, requiring manual splitting — resulting in 31% dosing inaccuracy per NIH pharmacy audit. Everin’s precision tablet format eliminates both issues.

Everin is not a universal solution — and no supplement should replace evaluation for underlying conditions like sleep apnea, restless legs syndrome, or anxiety disorders. But for families navigating developmentally appropriate sleep challenges — especially those tied to circadian misalignment, screen exposure, or neurodevelopmental differences — it offers a rigorously tested, pediatric-tailored option grounded in physiology, not marketing. Its strength lies not in novelty, but in fidelity: to evidence, to transparency, and to the real, measurable rhythms of childhood sleep.

Always discuss supplementation with your child’s pediatrician or a board-certified sleep specialist before initiating use. Keep Everin stored securely out of reach — like all melatonin-containing products, accidental ingestion by toddlers remains a leading cause of pediatric poison control calls (12,827 cases reported to AAPCC in 2023, up 527% since 2012).

RestWell Labs publishes all CoAs, clinical summaries, and safety reports publicly at everin.com/transparency — updated monthly. No login, no paywall, no marketing gatekeeping. Because when it comes to children’s health, clarity isn’t optional — it’s foundational.